182 related articles for article (PubMed ID: 32693228)
41. Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer.
Gouw ZAR; La Fontaine MD; Vogel WV; van de Kamer JB; Sonke JJ; Al-Mamgani A
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):960-968. PubMed ID: 32361007
[TBL] [Abstract][Full Text] [Related]
42. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
[TBL] [Abstract][Full Text] [Related]
43. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
[TBL] [Abstract][Full Text] [Related]
44. Preoperative
Cho JK; Ow TJ; Lee AY; Smith RV; Schlecht NF; Schiff BA; Tassler AB; Lin J; Moadel RM; Valdivia A; Abraham T; Gulko E; Neimark M; Ustun B; Bello JA; Shifteh K
Otolaryngol Head Neck Surg; 2017 Sep; 157(3):439-447. PubMed ID: 28608737
[TBL] [Abstract][Full Text] [Related]
45. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
46. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
47. Up-front PET/CT changes treatment intent in patients with head and neck squamous cell carcinoma.
Rohde M; Nielsen AL; Johansen J; Sørensen JA; Diaz A; Asmussen JT; Gerke O; Thomassen A; Gyldenkerne N; Døssing H; Bjørndal K; Høilund-Carlsen PF; Godballe C
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):613-621. PubMed ID: 29124279
[TBL] [Abstract][Full Text] [Related]
48. FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy.
Zschaeck S; Löck S; Leger S; Haase R; Bandurska-Luque A; Appold S; Kotzerke J; Zips D; Richter C; Gudziol V; Schreiber A; Zöphel K; Baumann M; Krause M
Radiother Oncol; 2017 Mar; 122(3):437-444. PubMed ID: 28222892
[TBL] [Abstract][Full Text] [Related]
49. Prospective comparative study of MRI including diffusion-weighted images versus FDG PET-CT for the detection of recurrent head and neck squamous cell carcinomas after (chemo)radiotherapy.
Driessen JP; Peltenburg B; Philippens MEP; Huijbregts JE; Pameijer FA; de Bree R; Janssen LM; Terhaard CHJ
Eur J Radiol; 2019 Feb; 111():62-67. PubMed ID: 30691667
[TBL] [Abstract][Full Text] [Related]
50. FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance.
Helsen N; Van den Wyngaert T; Carp L; Stroobants S
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1063-1071. PubMed ID: 29478080
[TBL] [Abstract][Full Text] [Related]
51. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.
Ng SH; Lin CY; Chan SC; Lin YC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Chang CJ; Wang JJ
PLoS One; 2014; 9(12):e115933. PubMed ID: 25531391
[TBL] [Abstract][Full Text] [Related]
52. PET/CT Versus Standard Imaging for Prediction of Survival in Patients with Recurrent Head and Neck Squamous Cell Carcinoma.
Rohde M; Nielsen AL; Pareek M; Johansen J; Sørensen JA; Diaz A; Nielsen MK; Christiansen JM; Asmussen JT; Nguyen N; Gerke O; Thomassen A; Alavi A; Høilund-Carlsen PF; Godballe C
J Nucl Med; 2019 May; 60(5):592-599. PubMed ID: 30315144
[TBL] [Abstract][Full Text] [Related]
53. Early Response Prediction of Multiparametric Functional MRI and
Martens RM; Koopman T; Lavini C; Brug TV; Zwezerijnen GJC; Marcus JT; Vergeer MR; Leemans CR; Bree R; Graaf P; Boellaard R; Castelijns JA
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008380
[TBL] [Abstract][Full Text] [Related]
54. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
55. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.
Yi JS; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY; Roh JL
J Surg Oncol; 2012 Nov; 106(6):708-12. PubMed ID: 22674652
[TBL] [Abstract][Full Text] [Related]
56. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.
Lonneux M; Hamoir M; Reychler H; Maingon P; Duvillard C; Calais G; Bridji B; Digue L; Toubeau M; Grégoire V
J Clin Oncol; 2010 Mar; 28(7):1190-5. PubMed ID: 20124179
[TBL] [Abstract][Full Text] [Related]
57. ¹⁸F-FDG PET/CT and MRI in the follow-up of head and neck squamous cell carcinoma.
Ghanooni R; Delpierre I; Magremanne M; Vervaet C; Dumarey N; Remmelink M; Lacroix S; Trotta N; Hassid S; Goldman S
Contrast Media Mol Imaging; 2011; 6(4):260-6. PubMed ID: 21861286
[TBL] [Abstract][Full Text] [Related]
58. Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma.
Abdalla AS; Sheybani ND; Khan SA
PET Clin; 2022 Apr; 17(2):213-222. PubMed ID: 35256298
[TBL] [Abstract][Full Text] [Related]
59. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma.
Bogowicz M; Riesterer O; Stark LS; Studer G; Unkelbach J; Guckenberger M; Tanadini-Lang S
Acta Oncol; 2017 Nov; 56(11):1531-1536. PubMed ID: 28820287
[TBL] [Abstract][Full Text] [Related]
60. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
